Cargando…
Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
Ovarian cancer is considered one of the most aggressive and deadliest gynecological malignancies worldwide. Unfortunately, the therapeutic methods that are considered the gold standard at this moment are associated with frequent recurrences. Survival in ovarian cancer is associated with the presence...
Autores principales: | Dumitru, Adrian, Dobrica, Elena-Codruta, Croitoru, Adina, Cretoiu, Sanda Maria, Gaspar, Bogdan Severus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603705/ https://www.ncbi.nlm.nih.gov/pubmed/36292922 http://dx.doi.org/10.3390/ijms232012067 |
Ejemplares similares
-
Vulvar and Vaginal Melanomas—The Darker Shades of Gynecological Cancers
por: Dobrică, Elena-Codruța, et al.
Publicado: (2021) -
Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022) -
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019) -
Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021) -
Gut Microbiome Changes in Gestational Diabetes
por: Ionescu, Ruxandra Florentina, et al.
Publicado: (2022)